The sector really seems bifurcated at this point. While the large caps have been pretty reliable winners the past couple of months, it seems like they are taking a break. Obviously, they are still close to their highs but more often than not they appear to struggle to gain and when they do the gains […]
Week’s Option Activity (2/20 ~ 3/04)
The following stocks had notable activity in their options during the past week(s): $CYTK (2/20): There were two large trades – one bullish and one bearish. (1) Bullish: 2,900 MAY risk reversals were purchased (stock at $9.85) for net 1.10 or total net cost of $319,000 (2,900 MAY 7.50 Strike Puts were sold for 1.90 […]
Week’s Option Activity (12/11~12/20)
The following stocks had notable activity in their options during the past week(s): $ARRY (12/11): 3,500 DEC/MAR 5.0 strike Put Time spreads (stock at $5.09) were sold for a net credit of 0.50 or total proceeds of $175,000. Seller makes money if stock stays above $4.50 by March expiration. $CNDO (12/13): 1,500 MAY 2.50 strike […]
Week’s Option Activity (7/8~7/12)
The following stocks had notable activity in their options during the past week: $CLDX (7/8): 1,000 AUG 22.0 strike Calls (stock at $21.27) were sold at 1.10 for total proceeds of $110,000. Seller makes money as long as stock trades less than $23.10 by August expiration. This trade is most likely paired with an equivalent […]
THLD – More uncertainty ahead for Threshold
As we previously suggested, Threshold Pharmaceuticals (NASDAQ: THLD) had some question marks about their future prospects of TH-302 in two key indications: pancreatic cancer and soft-tissue sarcoma. Recent data readouts have brought these issues into focus again. Although Threshold has a good cash position, we feel their lead (and only) drug, TH-302, will have a […]
THLD – What’s left for Threshold
In the first part of the year, Threshold Pharmaceuticals (THLD) delivered considerable returns for investors with a partnership deal for TH-302 and “positive” top-line Phase II data in pancreatic cancer. However, as the year has gone by, Threshold’s future for TH-302 has become less attractive. Even at current valuation, we still see further downside in […]
Option traders making moves
Today, we detected some large moves in the option markets for multiple names we follow. As we enter the fourth quarter, we suspect this increase in frequency. ARIAD Pharmaceuticals (NASDAQ: ARIA) The February $16 puts were very active today, with over 9,000 in volume (vs open interest of only 76 contracts). One trader sold two […]
Updates out of ESMO12
The European Society for Medical Oncology (ESMO) Congress 2012 kicked off this weekend and goes until October 2nd(Tuesday). Abstracts with data for those presentations that have already occurred can be viewed and searched here(link). We did get several updates from companies that we would like to review. First up is Threshold Pharmaceuticals (NASDAQ: THLD). On Saturday, they presented […]
Upcoming events for NKTR, THLD, ASTX
Given the plethora of data coming in the next 3 months, we thought we would do a few short series on biotech companies that will be quite busy this fall. We hope to do 3 or 4 installments in the next few weeks to give readers some broad coverage of what’s happening from small marketcap […]
ESMO12 Abstracts of interest
The European Society for Medical Oncology (ESMO) Congress 2012 kicks off on September 28th thru October 2nd. Abstract titles are currently able to be viewed and searched here(link), but no other descriptive information is available. Abstracts will be available before-hand on September 17th, with late-breaking abstracts coming during the Congress. Synta Pharmaceuticals (NASDAQ: SNTA) Several sources […]
Recent updates to our proprietary database
We wanted to walk you through the process of how we update our database and highlight a recent updates that we noticed. First off, we tend to update entries in the database about once a week, sometimes faster or slower depending on the number and importance of clinical/regulatory updates. (We get particularly hammered when the […]
Quick take on some upcoming FDA decisions and clinical data
A few comments to highlight some upcoming data or PDUFA events. Threshold Pharmaceuticals (NASDAQ: THLD) has been quite the stock the past few months after landing a partnership with Merck KGaA and reporting positive top-line PFS data from their Phase 2 study in pancreatic cancer. On Monday, April 2nd @ 10:30AM PST, Threshold will be […]
AMGN, REGN, MNTA & THLD – Quick Updates
Below are some brief note on about a dozen stocks that we felt compelled to brief subscribers on. Today, the briefing documents and panel attendees list for Amgen’s (NASDAQ: AMGN) Xgeva were posted. The panel is schedule for February 8, 2012 with a PDUFA date of April 26, 2012. Amgen hopes to add the indication […]
